Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.84 |
| ▸ | KDR | P35968 | 9/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823545 | 0.92 | BRAF (1.00) | BRAFKDRCYP2C9 | |
| SCHEMBL826636 | 0.90 | BRAF (0.78) | BRAFKDRCYP2C9MEN1KMT2A | |
| SCHEMBL15139583 | 0.89 | BRAF (0.70) | BRAFKDRCYP2C9 | |
| SCHEMBL823666 | 0.88 | BRAF (0.83) | BRAFKDR | |
| SCHEMBL823547 | 0.87 | BRAF (0.75) | BRAFKDRALDH1A1POLB | |
| SCHEMBL826287 | 0.85 | BRAF (0.62) | BRAFKDRMEN1KMT2AALDH1A1 | |
| SCHEMBL2192254 | 0.83 | BRAF (0.62) | BRAFKDRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL827228 | 0.81 | BRAF (0.72) | BRAFKDR | |
| SCHEMBL826153 | 0.80 | BRAF (0.55) | BRAFKDRMEN1KMT2AMAPT | |
| SCHEMBL15139585 | 0.80 | BRAF (0.85) | BRAFKDRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 1130/4885CYP2C9 1851/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 1130/4885CYP2C9 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.